ClinVar Miner

Submissions for variant NM_000152.5(GAA):c.2512C>T (p.Gln838Ter) (rs369532274)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Lysosomal Storage Disorder Variant Curation Expert Panel, ClinGen RCV001200861 SCV001371718 pathogenic Glycogen storage disease, type II 2020-05-04 reviewed by expert panel curation This variant, c.2512C>T (p.Gln838Ter), is a nonsense variant that is predicted to result in nonsense mediated decay and lack of gene product, meeting PVS1. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00006 in the African population, meeting PM2. It has been reported in two siblings with infantile onset Pompe disease who meet the ClinGen LSD VCEP's specifications for PP4, and who are compound heterozygous for the variant and c.2105G>T (p.Arg702Leu) (PMID 26167453). However, this in trans data will be used in the assessment of p.Arg702Leu and is not included here in order to avoid a circular argument. Another patient, with limb girdle muscular dystrophy, has been reported to be compound heterozygous for the variant and c.-32-13T>G. However, residual GAA activity was not provided, and therefore this data was not included (PMID 30564623). There is a ClinVar entry for this variant (Variation ID: 92479, 1 star review status) with one submitter classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PP4.
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000175263 SCV000226720 pathogenic not provided 2016-09-14 criteria provided, single submitter clinical testing
Broad Institute Rare Disease Group, Broad Institute RCV001200861 SCV001422608 pathogenic Glycogen storage disease, type II 2020-01-22 no assertion criteria provided curation The p.Gln838Ter variant in GAA has been reported in 2 African American individuals with Glycogen Storage Disease II, segregated with disease in 2 affected siblings from 1 family (PMID: 26167453), and has also been reported pathogenic by EGL Genetic Diagnostics in ClinVar (Variation ID: 92479). This variant has been identified in 0.006% (1/16188) of African chromosomes by the Genome Aggregation Database (gnomAD,; dbSNP rs369532274). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. This nonsense variant leads to a premature termination codon at position 838, which is predicted to lead to a truncated or absent protein. Loss of function of the GAA gene is an established disease mechanism in autosomal recessive Glycogen Storage Disease II. This variant has been reported in trans with a reported likely pathogenic variant and in 2 individuals with Glycogen Storage Disease II (PMID: 26167453; Variation ID: 92472). The phenotype of individuals heterozygous for this variant is highly specific for Glycogen Storage Disease II based on reduced GAA activity in fibroblasts or muscle tissue (PMID: 26167453). In summary, this variant meets criteria to be classified as pathogenic for Glycogen Storage Disease II in an autosomal recessive manner based on the predicted impact of the variant and occurrences with a reported likely pathogenic GAA variant in individuals with Glycogen Storage Disease II. ACMG/AMP Criteria applied: PVS1, PM2, PP4 (Richards 2015).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.